Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.42 |
| ▸ | FNTB | P49356 | 10/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 3/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499471 | 0.94 | FNTA (0.44) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| Trifluoroacetic Acid SCHEMBL6408587 | 0.85 | FNTA (0.46) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3500085 | 0.83 | FNTA (0.45) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3501605 | 0.80 | L3MBTL1 (0.45) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3500364 | 0.80 | TSHR (0.48) | FNTAFNTB | |
| SCHEMBL3499472 | 0.78 | FNTA (0.49) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3500544 | 0.78 | FNTA (0.46) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| Trifluoroacetic Acid SCHEMBL6275786 | 0.78 | FNTA (0.61) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3499620 | 0.77 | CACNA1G (0.47) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3499648 | 0.76 | FNTA (0.70) | FNTAFNTBCACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | claimed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| WO-2005089515-A9 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885CACNA1G 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.